Exagen reports Q2 EPS (28c), consensus (49c)

Reports Q2 revenue $14.1M, consensus $10.94M. “I’m very proud of the Exagen team and the results we have delivered as we operate a more effective organization, ensuring we continue to provide the best testing solutions to the Rheumatology community. Although these results have surpassed our expectations, our ambitions for the future remain even greater,” said John Aballi, President and Chief Executive Officer of Exagen.